Medicines for the Brain

We believe the key to treating neurodegenerative disease is to intervene early.

Millions of people worldwide suffer from neurodegenerative diseases that impair memory, focus and thinking and impact their ability to go about their daily lives. By applying our novel approach, we believe the synaptic dysfunction responsible for disease symptoms and progression can be reversed before the death of nerve cells.

Our Approach

A Focus On Neurodegenerative Disease

Dementia with Lewy Bodies

Patients with this disease accumulate protein deposits, called Lewy bodies, in the brain’s nerve cells. This negatively affects cognitive ability, including attention, judgement, and reasoning, along with motor function.

Frontotemporal Dementia

Frontotemporal dementia primarily affects the frontal and temporal lobes of the brain and is characterized by progressive deterioration in behavior, personality, and language abilities, leading to changes in social conduct, emotional regulation, and decision-making.

Stroke Recovery

Stroke, caused by blockage of arteries supplying blood to the brain, is the number one cause of long-term disability in adults. Most stroke survivors have some level of recovery after a stroke. However, in moderately severe and severe stroke the recovery is often incomplete.

HOPE THROUGH SCIENCE

Introducing Neflamapimod

We are developing neflamapimod – an investigational, orally administered, small molecule brain penetrant that inhibits the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction, the reversible aspect of the neurodegenerative process. The preclinical and clinical data with neflamapimod, including our ongoing Phase 2 RewinD-LB trial in patients with dementia with Lewy bodies (DLB), suggest that inhibition of p38 alpha by neflamapimod reverses the synaptic dysfunction that underlies development of symptoms and disease progression in the early stages of many neurological disorders.

Pipeline

CervoMed’s Approach for Dementia with Lewy Bodies

CervoMed In The News

Podcast: Biotech 2050 - Episode #210

Press Releases